RecruitingNCT03023202
UWCCC Molecular Tumor Board Registry
UWCCC Precision Medicine Molecular Tumor Board Registry
Sponsor
University of Wisconsin, Madison
Enrollment
10,000 participants
Start Date
Mar 30, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Clinically suspected or histologically confirmed solid or hematological malignancy
- Undergoing genetic testing of tumor
- Ability to understand written informed consent document
- Willingness to sign written informed consent document
Exclusion Criteria1
- Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERPMMTB (Precision Medicine Molecular Tumor Board)
PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03023202
Related Trials
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
NCT000710451 location
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
NCT049591752 locations
Influenza Vaccination Strategy for Patients With Hematologic Malignancy
NCT074858551 location
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
NCT029584623 locations
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
NCT053270231 location